DNA vs. COIN
DNA (Ginkgo Bioworks Holdings, Inc.) and COIN (Coinbase Global, Inc.) are both stocks. DNA operates in Biotechnology (Healthcare), while COIN operates in Financial Data & Stock Exchanges (Financial Services). Over the past 5 years, DNA returned -54.41%/yr vs -6.53%/yr for COIN. At a 0.42 correlation, their price movements are largely independent.
Performance
DNA vs. COIN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, DNA achieves a -5.05% return, which is significantly higher than COIN's -29.34% return.
DNA
- 1D
- -1.38%
- 1M
- 2.33%
- YTD
- -5.05%
- 6M
- -15.52%
- 1Y
- -11.74%
- 3Y*
- -53.33%
- 5Y*
- -54.41%
- 10Y*
- —
COIN
- 1D
- -0.41%
- 1M
- -18.24%
- YTD
- -29.34%
- 6M
- -40.26%
- 1Y
- -34.17%
- 3Y*
- 45.01%
- 5Y*
- -6.53%
- 10Y*
- —
DNA vs. COIN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
DNA Ginkgo Bioworks Holdings, Inc. | -5.05% | -15.38% | -85.47% | 0.00% | -79.66% | -21.68% |
COIN Coinbase Global, Inc. | -29.34% | -8.92% | 42.77% | 391.44% | -85.98% | -26.21% |
Correlation
The correlation between DNA and COIN is 0.37, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.37 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.38 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.43 |
Correlation (All Time) Calculated using the full available price history since Apr 19, 2021 | 0.42 |
Fundamentals
DNA:
$469.96M
COIN:
$42.31B
DNA:
-$5.40
COIN:
$2.90
DNA:
3.65
COIN:
7.59
DNA:
1.06
COIN:
3.14
DNA:
$121.84M
COIN:
$5.81B
DNA:
$99.27M
COIN:
$4.65B
DNA:
-$218.90M
COIN:
$1.68B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DNA vs. COIN — Risk / Return Rank
DNA
COIN
DNA vs. COIN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Coinbase Global, Inc. (COIN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DNA | COIN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.32 | ||
| Sortino ratioReturn per unit of downside risk | +0.82 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 0.96 | +0.10 |
| Calmar ratioReturn relative to maximum drawdown | -0.23 | -0.51 | +0.28 |
| Martin ratioReturn relative to average drawdown | -0.39 | -0.82 | +0.44 |
Loading charts...
Drawdowns
DNA vs. COIN - Drawdown Comparison
The maximum DNA drawdown since its inception was -99.10%, which is greater than COIN's maximum drawdown of -91.46%. Use the drawdown chart below to compare losses from any high point for DNA and COIN.
Loading charts...
Drawdown Indicators
| DNA | COIN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.10% | -91.46% | -7.64% |
Max Drawdown (1Y)Largest decline over 1 year | -66.05% | -66.39% | +0.34% |
Max Drawdown (3Y)Largest decline over 3 years | -94.72% | -66.39% | -28.33% |
Max Drawdown (5Y)Largest decline over 5 years | -99.10% | -90.90% | -8.20% |
Current DrawdownCurrent decline from peak | -98.68% | -61.94% | -36.74% |
Average DrawdownAverage peak-to-trough decline | -79.88% | -52.60% | -27.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 39.10% | 41.01% | -1.91% |
Volatility
DNA vs. COIN - Volatility Comparison
Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 21.11% compared to Coinbase Global, Inc. (COIN) at 19.52%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than COIN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DNA | COIN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.11% | 19.52% | +1.59% |
Volatility (6M)Calculated over the trailing 6-month period | 70.92% | 51.84% | +19.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 97.64% | 70.66% | +26.98% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 97.78% | 85.93% | +11.85% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 96.33% | 85.49% | +10.84% |
Dividends
DNA vs. COIN - Dividend Comparison
Neither DNA nor COIN has paid dividends to shareholders.
Financials
DNA vs. COIN - Financials Comparison
This section allows you to compare key financial metrics between Ginkgo Bioworks Holdings, Inc. and Coinbase Global, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
DNA and COIN have a correlation of 0.37, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
DNA has higher volatility (21.11%) compared to COIN (19.52%). In terms of maximum drawdown, DNA dropped -99.10% vs COIN's -91.46%.
DNA currently has the higher Sharpe Ratio (-0.16 vs -0.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for DNA and COIN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer